Skip to main content
SpringerLink
Log in

Treatment of Gonadotropin-Dependent Precocious Puberty

  • Chapter
Book cover When Puberty is Precocious

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Gonadotropin dependant precocious puberty is a heterogeneous disease with variable clinical presentations ranging from incomplete forms of precocious pubertal development to rapidly progressive forms. Although there is some controversy about the indications for treatment of central precocious puberty, in this chapter we review and clarify the indications as well as summarize the various methods available for monitoring therapy. Gonadotropin releasing hormone agonists (GnRHa) are currently considered the treatment of choice for central precocious puberty (CPP). Long-term outcome studies have shown that GnRHa have completely reversible suppressive effects on the hypothalamic-pituitary-gonadal axis, preserve final adult height, and have no long-term effects on bone mineral density and body composition in children with CPP. Newer therapies for use in CPP such as GnRH antagonists and third generation aromatase inhibitors are currently being studied and may be additional treatment options in the future

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Grumbach MM, Styne DM. Puberty: ontogeny, neuroendocrinology, physiology, and disorders. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, editors. Williams Textbook of Endocrinology, 9th edition. Philadelphia, PA: WB Saunders, 1998:1509–1625.

    Google Scholar 

  2. Bridges NA, Christopher JA, Hindmarsh PC, Brook CG. Sexual precocity: sex incidence and aetiology. Arch Dis Child 1994;70:116–118.

    PubMed  CAS  Google Scholar 

  3. Gonzales ER. For puberty that comes too soon, new treatment highly effective. JAMA 1982;248:1149–1152.

    Google Scholar 

  4. DeSanctis V, Corrias A, Rizzo V et al. Etiology of central precocious puberty in males: the results of the Italian Study Group for physiolo-pathology of puberty. J Pediatr Endocrinol Metab 2001;13(Suppl 1):687–693.

    Google Scholar 

  5. Cisternino M, Arrigo T, Pasquino AM et al. Etiology and age incidence of precocious puberty in girls: a multicenter study. J Pediatr Endrocrinol Metab 2000;13(Suppl 1):695–701.

    Google Scholar 

  6. Lee PA. Laboratory monitoring of children with precocious puberty. Arch Pediatr Adolesc Med 1994;148:369–376.

    PubMed  CAS  Google Scholar 

  7. Parker KL, Baens-Bailen RG, Lee PA. Depot leuprolide acetate dosing for sexual precocity. J Clin Endocrinol Metab 1991;73:50–52.

    PubMed  CAS  Google Scholar 

  8. Neely EK, Hintz RL, Parker B et al. Two-year results of treatment with depo leuprolide acetate for central precocious puberty. J Pediatr 1992;121:634–640.

    PubMed  CAS  Google Scholar 

  9. Oerter KE, Uriarte MM, Rose SR et al. Gonadotropin secretory dynamics during puberty in normal girls and boys. J Clin Endocrinol Metab 1990;71:1251–1258.

    PubMed  CAS  Google Scholar 

  10. Eckert KL, Wilson DM, Bachrach LK et al. A single-sample, subcutaneous gonadotropin releasing hormone test for central precocious puberty. Pediatrics 1996;97:517–519.

    PubMed  CAS  Google Scholar 

  11. Neely EK, Hintz RL, Wilson DM et al. Normal ranges for immunochemiluminometric gonadotropin assays. J Pediatr 1995;127:40–46.

    PubMed  CAS  Google Scholar 

  12. Neely EK, Wilson DM, Lee PA et al. Spontaneous serum gonadotropin concentration assays. J Pediatr 1995;127:47–52.

    PubMed  CAS  Google Scholar 

  13. Demir A, Alfthan H, Stenman UH et al. A clinically useful methods for detecting gonadotropins in children: assessment of leutinizing hormone and follicle-stimulating hormone from urine as an alternative to serum by ultrasensitive time-resolved immunofluorometric assays. Pediatr Res 1994;36:221–226.

    PubMed  CAS  Google Scholar 

  14. Lee PA. Central precocious puberty, an overview of diagnosis, treatment, and outcome. Endocrinol Metabol Clin North Am 1999;28:901–918.

    CAS  Google Scholar 

  15. Pescovitz OH, Comite F, Hench K et al. The NIH experience with precocious puberty: diagnostic subgroups and response to short term leutinizing hormone-releasing hormone analogue therapy. J Pediatr 1986;108:47–54.

    PubMed  CAS  Google Scholar 

  16. Stanhope R. Premature thelarche: clinical follow-up and indication for treatment. J Pediatr Endocrinol Metab 2000;13(Suppl 1):827–830.

    PubMed  Google Scholar 

  17. Klein HO. Precocious puberty; who has it? Who should be treated? J Clin Endocrinol Metab 1999;84:411–414.

    PubMed  CAS  Google Scholar 

  18. Rosenfield R. Selection of children with precocious puberty for treatment with gonadotropin releasing hormone analogs. J Pediatr 1994;124:989–991.

    PubMed  CAS  Google Scholar 

  19. Léger J, Reynaud R, Czernichow P. Do all girls with apparent idiopathic precocious puberty require gonadotrophin-releasing hormone treatment? J Pediatr 2000;137:819–825.

    PubMed  Google Scholar 

  20. Sonis WA, Comite F, Blue J et al. Behavioral problems and social competence in girls with true precocious puberty. J Pediatr 1985;106:156–160.

    PubMed  CAS  Google Scholar 

  21. Ehrhardt AA, Meyer-Bahlberg HFL, Bell JJ. Idiopathic precocious puberty in girls: psychiatric follow-up in adolescence. J Am Acad Child Psychiatry 1984;23:23–33.

    PubMed  CAS  Google Scholar 

  22. Baumann DA, Landolt MA, Wetterwald R et al. Psychological evaluation of young women after medical treatment for central precocious puberty. Horm Res 2001;56:45–50.

    PubMed  CAS  Google Scholar 

  23. Cassio A, Cacciari E, Balsamo A, Bal M, Tassinari D. Randomized trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years. Arch Dis Child 1999;81:329–332.

    PubMed  CAS  Google Scholar 

  24. Kaplan SL, Grumbach MM. Clinical review 14: pathophysiology and treatment of sexual precocity. J Clin Endocrinol Metab 1990;71:785–789.

    PubMed  CAS  Google Scholar 

  25. Palmert MR, Malin HV, Boepple PA. Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients. J Clin Endocrinol Metab 1999;84:415–423.

    PubMed  CAS  Google Scholar 

  26. Stanhope R, Pringle PJ, Adams J, Jeffcoate SL, Brook CG. Spontaneous gonadotrophin pulsatility and ovarian morphology in girls with central precocious puberty treated with cyproterone acetate. Clin Endocrinol (Oxf) 1985;23:547–553.

    CAS  Google Scholar 

  27. Werder EA, Murset G, Zachmann M, Brook CG, Prader A. Treatment of precocious puberty with cyproterone acetate. Pediatr Res 1974;8:248–256.

    PubMed  CAS  Google Scholar 

  28. Sadeghi-Nejad A, Kaplan SL, Grumbach, MM. The effects of medroxyprogesterone acetate on adrenocortical function in children with precocious puberty. J Pediatr 1971;78:616–624.

    PubMed  CAS  Google Scholar 

  29. Conn PM, Crowley WFJ. Gonadotropin-releasing hormone and its analogues. N Engl J Med 1990;324:93–103.

    Google Scholar 

  30. Cornea A, Janovick JA, Maya-Nunez G, Conn PM. Gonadotropin-releasing hormone receptor microaggregation. Rate monitored by fluorescence resonance energy transfer. J Biol Chem 2001;276:2153–2158.

    CAS  Google Scholar 

  31. Conn PM, Crowley WFJ. Gonadotropin releasing hormone and its analogs. Annu Rev Med 1994;45:391–405.

    PubMed  CAS  Google Scholar 

  32. Lahlou N, Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab 2000;13(Suppl 1):723–737.

    PubMed  Google Scholar 

  33. Antoniazzi F, Cisternino M, Nizzoli G et al. Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonists treatment. Acta Paediatr 1994;83:1052–1056.

    PubMed  CAS  Google Scholar 

  34. Tuvemo T, Gustafsson J, Proos LA. Swedish Growth Hormone Group: suppression of puberty in girls with short-acting intranasal versus subcutaneous depot GnRH agonist. Horm Res 2002;57:27–31.

    PubMed  CAS  Google Scholar 

  35. Neely EK, Hintz RL, Parker B et al. Two year results of treatment with depot leuprolide acetate for central precocious puberty. J Pediatr 1992;121:634–640.

    PubMed  CAS  Google Scholar 

  36. Parker KL, Baens-Bailon RG, Lee PA. Depot leuprolide acetate dosage for sexual precocity. J Clin Endocrinol Metab 1991;73:50–52.

    PubMed  CAS  Google Scholar 

  37. Bouvattier C, Coste J, Rodrique D et al. Lack of effect of GnRH agonists on final heights in girls with advanced puberty: a randomized long-term pilot study. J Clin Endocrinol Metab 1999;84:3575–3578.

    PubMed  CAS  Google Scholar 

  38. Lee M, Browneller R, Wu Z, Jung A, Ratanawong C, Sharifi R. Therapeutic effects of leuprorelin microspheres in prostate cancer. Adv Drug Deliv Rev 1997;28:43–70.

    Google Scholar 

  39. Carel JC, Lahlou N, Jaramillo O et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 2002;87:4111–4116.

    PubMed  CAS  Google Scholar 

  40. Schroeter M, Baus I, Sippell WG, Partsch CJ. Long-term suppression of pituitary-gonadal function with three-month depot of leuprorelin acetate in a girl with central precocious puberty. Horm Res 2002;58:292–296.

    PubMed  CAS  Google Scholar 

  41. Hirsch HJ, Gillis D, Strich D et al. The histrelin implant: a novel treatment for central precocious puberty. Pediatrics 2005;116:e798–e802.

    PubMed  Google Scholar 

  42. Huirne JA, Lambalk CB. Gonadotropin releasing hormone receptor antagonists. Lancet 2001;358:1793–1803.

    PubMed  CAS  Google Scholar 

  43. Wu MH, Lin SJ, Wu LH, Cheng YC, Chou YY, Pan HA. Clinical suppression of precocious puberty with cetrorelix after failed treatment with GnRH agonist in a girl with gonadotrophin-independent precocious puberty. Reprod Biomed Online 2005;11(1):18–21.

    PubMed  Google Scholar 

  44. Roth CL, Brendel L, Ruckert C, Hartmann K. Antagonistic and agonistic GnRH analogue treatment of precocious puberty: tracking gonadotropin concentrations in urine. Horm Res 2005;63:257–262.

    PubMed  CAS  Google Scholar 

  45. Roth C, Hegemann F, Hildebrandt J et al. Pituitary and gonadal effects of GnRH (gonadotropin releasing hormone) analogues in two peripubertal female rat models. Pediatr Res 2004;55:126–133.

    PubMed  CAS  Google Scholar 

  46. Kappy MS, Stuart T, Perelman A, Clemons R. Suppression of gonadotropin secretion by a long acting gonadotropin releasing hormone analog (leuprolide acetate, lupron depot) in children with precocious puberty. J Clin Endocrinol Metab 1989;77:327–329.

    Google Scholar 

  47. Roger M, Chaussain JL, Berlier P et al. Long term treatment of male and female precocious puberty by periodic administration of a long acting preparation of D-Trp6-luteinizing hormone releasing hormone microcapsules. J Clin Endocrinol Metab 1986;62:670–677.

    PubMed  CAS  Google Scholar 

  48. Yeshaya A, Kauschansky A, Orvieto R, Nussinovitch M, Ben-Rafael Z. Prolonged vaginal bleeding during central precocious puberty therapy with a long acting gonadotropin releasing hormone agonist. Acta Obstet Gynecol Scand 1998;77:327–329.

    PubMed  CAS  Google Scholar 

  49. Manasco PK, Pescovitz OH, Blizzard RM. Local reactions to depot leuprolide therapy for central precocious puberty. J Pediatr 1993;123:334–335.

    PubMed  CAS  Google Scholar 

  50. Tonini G, Marinoni S, Forelo V, Rustico M. Local reactions to luteinizing hormone releasing hormone analog therapy. J Pediatr 1995;126:159–160.

    PubMed  CAS  Google Scholar 

  51. Tonini G, Lazzerini M. Side effects of GnRH analogue treatment in childhood. J Pediatr Endocrinol Metab 2000;13:795–803.

    PubMed  Google Scholar 

  52. Styne DM, Harris DA, Egli CA et al. Treatment of true precocious puberty with a potent luteinizing hormone releasing hormone factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic pituitary gonadal axis. J Clin Endocrinol Metab 1985;61:142–151.

    PubMed  CAS  Google Scholar 

  53. Lawson ML, Cohen N. A single sample subcutaneous luteinizing hormone (LH)-releasing hormone (LHRH) stimulation test for monitoring LH suppression in children with central precocious puberty receiving LHRH agonist. J Clin Endocrinol Metab 1999;84:4536–4540.

    PubMed  CAS  Google Scholar 

  54. Salerno M, Di Maio S, Gasparini N, Mariano A, MAcchia V, Tenore A. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment. Horm Res 1998;50:205–211.

    CAS  Google Scholar 

  55. Bhatia S, Neely EK, Wilson DM. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics 2002;109:E30.

    PubMed  Google Scholar 

  56. Brito VN, Latronico AC, Arnhold IJP, Mendonca BB. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin dependant precocious puberty in girls. J Clin Endocrinol Metab 2004;89:4338–4342.

    PubMed  CAS  Google Scholar 

  57. Bidlingmaier F, Butenandt O, Knorr D. Plasma gonadotropins and estrogens in girls with idiopathic precocious puberty. Pediatr Res 1977;11:91–94.

    PubMed  CAS  Google Scholar 

  58. Brauner R, Malandry F, Fontoura M, Pevot C, Souberbielle JC, Rappaport R. Idiopathic central precocious puberty in girls as a model of the effect of plasma estradiol level on growth, skeletal maturation and plasma insulin-like growth factor 1. Horm Res 1991;36:116–120.

    PubMed  CAS  Google Scholar 

  59. Witchel SF, Baens-Bailon RG, Lee PA. Treatment of central precocious puberty: comparison of urinary gonadotropin excretion and gonadotropin releasing hormone (GnRH) stimulation tests in monitoring GnRH analog therapy. J Clin Endocrinol Metab 1996;81:1353–1356.

    PubMed  CAS  Google Scholar 

  60. Carel JC, Roger M, Ispas S et al. Final height after long-term treatment with Triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. J Clin Endocrinol Metab 1999;84:1973–1978.

    PubMed  CAS  Google Scholar 

  61. Ohyama K, Tanaka T, Tachibana K et al. Timing for discontinuation of treatment with a longacting gonadotropin-releasing hormone analog in girls with central precocious puberty. Endocr J 1998;45:351–356.

    PubMed  CAS  Google Scholar 

  62. Arrigo T, Cisternino M, Galluzzi F et al. Analysis of the factors affecting auxological response to GnRH analog treatment and adult height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol 1999;141:140–144.

    PubMed  CAS  Google Scholar 

  63. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr. Increased final height in precocious puberty after long term treatment with LHRH agonists: The National Institute of Health experience. J Clin Endocrinol Metab 2001;86:4711–4716.

    PubMed  CAS  Google Scholar 

  64. Jay N, Mansfield MJ, Blizzard RM et al. Ovulation and menstrual function of adolescents with central precocious puberty after therapy with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 1992;75:890–894.

    PubMed  CAS  Google Scholar 

  65. Heger S, Partsch C-J, Wolfgang SG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999;84:4583–4590.

    PubMed  CAS  Google Scholar 

  66. Tanaka T, Niimi H, Matsuo N et al. Results of long-term follow up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese study group on central precocious puberty. J Clin Endocrinol Metab 2005;90:1371–1376.

    PubMed  CAS  Google Scholar 

  67. Schroor EJ, Van Weissenbruch MM, and Delemarre-van de Waal HA. Long-term GnRH-agonist treatment does not postpone central development of the GnRH pulse generator in girls with idiopathic precocious puberty. J Clin Endocrinol Metab 1995;80:1696–1701.

    PubMed  CAS  Google Scholar 

  68. Bridges NA, Cooke A, Healy JR, Hindmarsh PC, Brook CGD. Ovaries in sexual precocity. Clin Endocrinol (Oxf) 1995;42:135–140.

    CAS  Google Scholar 

  69. Baek-Jensen AM, Brocks V, Holm K, Laursen EM, Muller J. Central precocious puberty in girls: internal genitalia before, during, and after treatment with long-acting gonadotropin-releasing hormone analogues. J Pediatr 1998;132:105–108.

    Google Scholar 

  70. Ambrosino MM, Hernanz-Schulman M, Genieser NB, Sklar CA, Fefferman NR, David R. Monitoring of girls undergoing medical therapy for isosexual precocious puberty. J Ultrasound Med 1994;13:501–508.

    PubMed  CAS  Google Scholar 

  71. Weinbauer GF, Respondek M, Themann H, Nieschlag E. Reversibility of long term effects on GnRH agonist administration on testicular histology and sperm production in the nonhuman primate. J Androl 1987;8:319–329.

    PubMed  CAS  Google Scholar 

  72. Johansson T, Ritzen EM. Very long term follow-up of girls with early and late menarche. Endocr Dev 2005;8:126–136.

    PubMed  Google Scholar 

  73. Stattin H. Adult outcome of early puberty in girls. Pediatr Res 2001;49:6.

    Google Scholar 

  74. Paoletti AM, Serra CG, Cagnacci A et al. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril 1996;65:707–710.

    PubMed  CAS  Google Scholar 

  75. Goldray D, Weisman Y, Jaccard N, Merdler C, Chen J, Matzkin H. Decreased bone density in elderly men treated with gonadotropin-releasing agonist decapeptyl (d-TRP6-GnRH). J Clin Endocrinol Metab 1993;76:288–290.

    PubMed  CAS  Google Scholar 

  76. Saggese G, Bertelloni S, Baroncelli GI, Pardi D, Cinquanta L. Bone loss during gonadotropin-releasing hormone agonist treatment in girls with true precocious puberty is not due to impairment of calcitonin secretion. J Clin Invest 1991;14:231–236.

    CAS  Google Scholar 

  77. Van Der Sluis IM, Boot AM, Krenning EP, Drop SL, De Muinck Keiser-Schrama S. Longitudinal follow-up of bone mineral density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab 2002;87:506–512.

    PubMed  Google Scholar 

  78. Antoniazzi F, Bertolodo F, Zamboni G et al. Bone mineral metabolism in girls with precocious puberty during gonadotropin-releasing agonist treatment. Eur J Endocrinol 1995;133:412–417.

    PubMed  CAS  Google Scholar 

  79. Boot AM, De Muinck Keiser-Schrama S, Pols HA, Drop SL. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious puberty. J Clin Endocrinol Metab 1998;83:370–373.

    PubMed  CAS  Google Scholar 

  80. Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G, Saggese G. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females. Eur J Pediatr 1998;157:363–367.

    PubMed  CAS  Google Scholar 

  81. Antoniazzi F, Zamboni G, Bertoldo F et al. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation. J Clin Endocrinol Metab 2003;88:1096–1101.

    PubMed  CAS  Google Scholar 

  82. Feuillan PP, Jones JV, Brnes K, Oerter-klein K, Cutler GB Jr. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab 1999;84:44–49.

    PubMed  CAS  Google Scholar 

  83. Palmert MR, Mansfield MJ, Crowley WF Jr, Crigler JF, Crawford JD, Boepple PA. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999;84:4480–4488.

    PubMed  CAS  Google Scholar 

  84. Arrigo T, De Luca F, Antoniazzi F et al. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol 2004;150:533–537.

    PubMed  CAS  Google Scholar 

  85. Sigurjonsdottir TJ, Hayles AB. Precocious puberty, a report of 96 cases. Am J Dis Child 1968;115:309–321.

    PubMed  CAS  Google Scholar 

  86. Martinez L, Preece MA, Grant DB. Body proportions in precocious puberty. Acta Pediatr Scand 1984;73:185–188.

    CAS  Google Scholar 

  87. Antoniazzi F, Cisternino M, Nizoli G et al. Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonist treatment. Acta Paediatr 1997;83:1052–1056.

    Google Scholar 

  88. Kauli R, Galatzer A, Kornreich L, Lazar L, Pertzelan A, Laron Z. Adult height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method. Horm Res 1997;47:54–61.

    CAS  Google Scholar 

  89. Mul D, Bertelloni S, Carel JC, Saggesse G, Ghaussain JL, Oostdijk W. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty: adult height results. Horm Res 2002;58:1–7.

    PubMed  CAS  Google Scholar 

  90. Paul D, Conte FA, Grumbach MM, Kaplan SL. Long term effect of gonadotropin-releasing hormone agonist therapy on final height and near final height in 26 children with true precocious puberty treated at a median age of less than 5 years. J Clin Endocrinol Metab 1995;80:546–551.

    PubMed  CAS  Google Scholar 

  91. Kletter GB, Kelch RP. Clinical review 60: effects of gonadotropin-releasing hormone analog therapy on adult stature in precocious puberty. J Clin Endocrinol Metab 1994;79:331–334.

    PubMed  CAS  Google Scholar 

  92. Cassio A, Cacciari F, Balsamo A, Bal M, Tassinari D. Randomized trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years. Arch Dis Child 1999;81:329–332.

    PubMed  CAS  Google Scholar 

  93. Bouvattier C, Coste J, Rodrigue D et al. Lack of effect of GnRH agonists on final height in girls with advanced puberty: a randomized long-term pilot study. J Clin Endocrinol Metab 1999;84:3575–3578.

    PubMed  CAS  Google Scholar 

  94. Micillo M, Salerno M, Officiosa A et al. Near final height after GnRH agonist treatment in central precocious puberty. J Pediatr Endocrinol Metab 2000;13(Suppl 1):787–790.

    PubMed  Google Scholar 

  95. Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423–441.

    PubMed  CAS  Google Scholar 

  96. Antoniazzi F, Arrigo T, Cisternino M et al. End results in central precocious puberty with GnRH analog treatment: the data of the Italian Study Group for Physiopathology of puberty. J Pediatr Endocrinol Metab 2000;13(Suppl 1):773–780.

    PubMed  Google Scholar 

  97. Partsch CJ, Heger S, Sippell WG. The German Decapeptyl Study Group. Treatment of central precocious puberty: lessons from a 15 years, prospective trial. J Pediatr Endocrinol Metab 2000;13:747–758.

    PubMed  Google Scholar 

  98. Walvoord EC, Pescovitz OH. Combined use of growth hormone and gonadotropin-releasing hormone analogues in precocious puberty: theoretic and practical considerations. Pediatrics 1999;104:1010–1014.

    PubMed  CAS  Google Scholar 

  99. Kamp GA, Manasco PK, Barnes KM et al. Low growth hormone levels are related to increased body mass index and do not reflect impaired growth in luteinizing hormone-releasing hormone agonist-treated children with precocious puberty. J Clin Endocrinol Metab 1991;72:301–307.

    PubMed  CAS  Google Scholar 

  100. DiMartino-Nardi J, Wu R, Varner R, Wong WL, Saenger P. The effect of luteinizing hormone-releasing hormone analog for central precocious puberty on growth hormone (GH) and GH-binding protein. J Clin Endocrinol Metab 1994;78:664–668.

    PubMed  CAS  Google Scholar 

  101. Juul A, Scheike T, Nielsen CT, Krabbe S, Muller J, Skakkebaek NE. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate). J Clin Endocrinol Metab 1995;80:3059–3067.

    PubMed  CAS  Google Scholar 

  102. Galluzzi F, Salti R, Bindi G, Pasquini E, La Cauza C. Adult height comparison between boys and girls with precocious puberty after long-term gonadotrophin-releasing hormone analogue therapy. Acta Paediatr 1998;87:521–527.

    PubMed  CAS  Google Scholar 

  103. Sklar CA, Rothenberg S, Blumberg D, Oberfield SE, Levine LS, David R. Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion. J Clin Endocrinol Metab 1991;73:734–738.

    PubMed  CAS  Google Scholar 

  104. Saggese G, Pasquino AM, Bertelloni S et al. Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis. Acta Paediatr 1995;84:299–304.

    PubMed  CAS  Google Scholar 

  105. Cisternino M, Draghi M, Lauriola S et al. The acid-labile subunit of human ternary insulin-like growth factor-binding protein complex in girls with central precocious puberty before and during gonadotropin-releasing hormone analog therapy. J Clin Endocrinol Metab 2002;87:4629–4633.

    PubMed  CAS  Google Scholar 

  106. Weise M, Flor A, Barnes KM, Cutler GB Jr, Baron J. Determinants of growth during gonadotropin-releasing hormone analog therapy for precocious puberty. J Clin Endocrinol Metab 2004;89:103–107.

    PubMed  CAS  Google Scholar 

  107. Weise M, De-Levi S, Barnes KM, Gafni RI, Abad V, Baron J. Effects of estrogen on growth plate senescence and epiphyseal fusion. Proc Natl Acad Sci USA 2001;98:6871–6876.

    PubMed  CAS  Google Scholar 

  108. Tato L, Saggese G, Cavallo L et al. Use of combined Gn-RH agonist and hGH therapy for better attaining the goals in precocious puberty treatment. Horm Res 1995;44(Suppl 3):49–54.

    PubMed  CAS  Google Scholar 

  109. Pasquino AM, Pucarelli I, Segni M, Matrunola M, Cerroni F. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone. J Clin Endocrinol Metab 1999;84:449–452.

    PubMed  CAS  Google Scholar 

  110. Pucarelli I, Segni M, Ortore M, Moretti A, Iannaccone R, Pasquino AM. Combined therapy with GnRH analog plus growth hormone in central precocious puberty. J Pediatr Endocrinol Metab 2000;13(Suppl 1):811–820.

    PubMed  Google Scholar 

  111. Lin-Su K, Vogiatzi MG, Marshall I et al. Treatment with growth hormone and luteinizing hormone releasing hormone analog improves final adult height in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2005;90:3318–3325.

    PubMed  CAS  Google Scholar 

  112. Sklar CA. Growth and neuroendocrine dysfunction following therapy for childhood cancer. Pediatr Clin North Am 1997;44:489–503.

    PubMed  CAS  Google Scholar 

  113. Moore DC, Tattoni DS, Limbeck GA et al. Studies of anabolic steroids: v. effect of prolonged oxandrolone administration on growth in children and adolescents with uncomplicated short stature. Pediatrics 1976;58:412–422.

    PubMed  CAS  Google Scholar 

  114. Marti-Henneberg C, Niirianen AK, Rappaport R. Oxandrolone treatment of constitutional short stature in boys during adolescence: effect on linear growth, bone age, pubic hair, and testicular development. J Pediatr 1975;86:783–788.

    PubMed  CAS  Google Scholar 

  115. Malhotra A, Poon E, Tse WY, Pringle PJ, Hindmarsh PC, Brook CG. The effects of oxandrolone on the growth hormone and gonadal axes in boys with constitutional delay of growth and puberty. Clin Endocrinol (Oxf) 1993;38:393–398.

    CAS  Google Scholar 

  116. Ulloa-Aguirre A, Blizzard RM, Garcia-Rubi E et al. Testosterone and oxandrolone, a nonaromatizable androgen, specifically amplify the mass and rate of growth hormone (GH) secreted per burst without altering GH secretory burst duration or frequency or the GH half-life. J Clin Endocrinol Metab 1990;71:846–854.

    PubMed  CAS  Google Scholar 

  117. Carrascosa A, Audi L, Ferrandez MA, Ballabriga A. Biological effects of androgens and identification of specific dihydrotestosterone-binding sites in cultured human fetal epiphyseal chondrocytes. J Clin Endocrinol Metab 1990;70:134–140.

    PubMed  CAS  Google Scholar 

  118. Somjen D, Weisman Y, Mor Z, Harell A, Kaye AM. Regulation of proliferation of rat cartilage and bone by sex steroid hormones. J Steroid Biochem Mol Biol 1991;40:717–723.

    PubMed  CAS  Google Scholar 

  119. Schwartz Z, Nasatzky E, Ornoy A, Brooks BP, Soskolne WA, Boyan BD. Gender-specific, maturation-dependent effects of testosterone on chondrocytes in culture. Endocrinology 1994;34:1640–1647.

    Google Scholar 

  120. Vottero A, Pedori S, Verna M et al. Final height in girls with central idiopathic precocious puberty treated with gonadotropin-releasing hormone analog and oxandrolone. J Clin Endocrinol Metab 2006;91:1284–1287.

    PubMed  CAS  Google Scholar 

  121. Karmazin A, Moore WV, Popovic J, Jacobson JD. The effects of letrozole on bone age progression, predicted adult height, and adrenal gland function. J Pediatr Endocrinol Metab 2005;18:285–293.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Zeina M. Nabhan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emily C. Walvoord MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Pediatrics and Cellular and Integrative Physiology, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN

    Ora H. Pescovitz MD

  2. Section of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN, USA

    Emily C. Walvoord MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc.

About this chapter

Cite this chapter

Nabhan, Z.M., Walvoord, E.C. (2007). Treatment of Gonadotropin-Dependent Precocious Puberty. In: Pescovitz, O.H., Walvoord, E.C. (eds) When Puberty is Precocious. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-59745-499-5_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-499-5_16

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-742-6

  • Online ISBN: 978-1-59745-499-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation